Denmark’s Novonesis to Invest ₹6,660 Crore in Maharashtra Facility Expansion
- Novonesis plans to invest ₹6,660 crore to nearly quadruple its Patalganga facility in Maharashtra by 2030 to increase enzyme production capacity and meet global biosolutions demand while strengthening its supply network.
- The expanded facility will serve emerging markets, including India, South Asia, the Middle East, and Africa, which are key growth regions expected to outpace developed markets.
- Novonesis will build the Patalganga plant with advanced water and energy efficiency measures to reduce freshwater use and emissions, aiming for sustainable, zero-emission production.
- The investment is part of Novonesis's global expansion strategy, with significant capital expenditure focused on enhancing production closer to customers in emerging markets.
12 Articles
12 Articles
Denmark’s Novonesis to invest ₹6,660 crore in Maharashtra facility expansion
The investment underscores Novonesis’ strategy of expanding its global manufacturing footprint in markets with strong growth potential; strengthening supply capabilities for customers across Asia, the Middle East and Africa.
Novonesis will invest billions to create one of the world's most advanced enzyme factories in India
BT
Novonesis will invest billions to create one of the world's most advanced enzyme factories in India.
The Manila Times
ChiniMandiNovonesis to build next generation enzyme production facility in India
Novonesis will invest €600 million to expand its site in Patalganga and build a state-of-the-art facility. This marks another step in the company's long-term growth...
Novonesis Invests €600 Million in Advanced Enzyme Production Facility in India
(IN BRIEF) Novonesis will invest €600 million to expand its Patalganga facility in India and build a next-generation enzyme production plant expected to be fully operational in 2030. The investment will increase capacity for biosolutions used across industries including biofuels, … Read the full press release →
Coverage Details
Bias Distribution
- 66% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
